Drug Profile
MV 140
Alternative Names: MV140; UROMUNELatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Immunotek SL
- Developer Immunotek SL; Queens University
- Class Anti-infectives; Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Urinary tract infections
Most Recent Events
- 03 Oct 2023 Inmunotek SL completes expanded access programme for Urinary tract infections (Recurrent) in Belgium, Czech Republic, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Romania, Serbia, Slovakia, Slovenia, Sweden and Turkey (NCT04173013)
- 30 Jun 2023 MV 140 is available through various special access programs for the treatment of Urinary tract infections in the UK, the Netherlands, Sweden, Norway, Spain, Australia and New Zealand (Red Leaf Medical website, June 2023)
- 28 Apr 2023 Efficacy and adverse events data from a clinical trial in Urinary tract infections presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)